Abstract
Glucocorticoids are used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) but many patients develop glucocorticoid resistance on relapse. The ligand-activated glucocorticoid receptor inhibits activity of the AP-1 transcription factor and the purpose of this study was to test the hypothesis that up-regulation or overexpression of AP1-binding activity may be an important mechanism of glucocorticoid resistance in ALL and CLL. In vitro sensitivity of patient blasts to prednisolone was measured using th
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Base Sequence
-
Blotting, Northern
-
Blotting, Western
-
Child, Preschool
-
DNA Primers
-
Drug Resistance, Neoplasm*
-
Female
-
Glucocorticoids / pharmacology*
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
-
Proto-Oncogene Proteins c-fos / metabolism
-
Proto-Oncogene Proteins c-jun / metabolism
-
Transcription Factor AP-1 / physiology*
Substances
-
DNA Primers
-
Glucocorticoids
-
Proto-Oncogene Proteins c-fos
-
Proto-Oncogene Proteins c-jun
-
Transcription Factor AP-1